{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:00:51Z","timestamp":1784833251595,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,23]]},"DOI":"10.7759\/cureus.113243","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:08:31Z","timestamp":1784830111000},"source":"Crossref","is-referenced-by-count":0,"title":["Association of Histopathologic Characteristics in Diagnostic Prostate Biopsies With Decipher Genomic Classifier Risk Groups"],"prefix":"10.7759","author":[{"given":"Selin","family":"Kurt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Usman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrison","family":"Pease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70028","article-title":"Prostate cancer statistics, 2025","volume":"75","author":"Kratzer TB","year":"2025","unstructured":"Kratzer TB, Mazzitelli N, Star J, Dahut WL, Jemal A, Siegel RL. Prostate cancer statistics, 2025. CA Cancer J Clin. 2025, 75:485-97. 10.3322\/caac.70028","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin MB","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, et al.. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017, 67:93-9. 10.3322\/caac.21388","journal-title":"CA Cancer J Clin"},{"key":"ref4","article-title":"Prostate cancer treatment (PDQ\u00ae): health professional version","year":"2002","unstructured":"Prostate cancer treatment (PDQ\u00ae). health professional version. PDQ Cancer Information Summaries. National Cancer Institute, Bethesda, MD; 2002."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors","volume":"82","author":"Netto GJ","year":"2022","unstructured":"Netto GJ, Amin MB, Berney DM, et al.. The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors. Eur Urol. 2022, 82:469-82. 10.1016\/j.eururo.2022.07.002","journal-title":"Eur Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142334","article-title":"The role of genomic scores in the management of prostate cancer patients: a comprehensive narrative review","volume":"17","author":"Viti A","year":"2025","unstructured":"Viti A, Quarta L, Zaurito P, et al.. The role of genomic scores in the management of prostate cancer patients: a comprehensive narrative review. Cancers (Basel). 2025, 17:10.3390\/cancers17142334","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.7671","article-title":"Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG\/RTOG 9601 randomized clinical trial","volume":"7","author":"Feng FY","year":"2021","unstructured":"Feng FY, Huang HC, Spratt DE, et al.. Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG\/RTOG 9601 randomized clinical trial. JAMA Oncol. 2021, 7:544-52. 10.1001\/jamaoncol.2020.7671","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.7089","article-title":"A prospective validation of the decipher genomic classifier in men with early localized prostate cancer: the VANDAAM study","volume":"24","author":"Yamoah K","year":"2025","unstructured":"Yamoah K, Trivedi P, Awasthi S, et al.. A prospective validation of the decipher genomic classifier in men with early localized prostate cancer: the VANDAAM study. J Natl Compr Canc Netw. 2025, 24:10.6004\/jnccn.2025.7089","journal-title":"J Natl Compr Canc Netw"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5152\/eurasianjmed.2025.25828","article-title":"The clinical impact of the Decipher genomic classifier in prostate cancer","volume":"57","author":"Li S","year":"2025","unstructured":"Li S, A Berg S, Sayan M. The clinical impact of the Decipher genomic classifier in prostate cancer. Eurasian J Med. 2025, 57:1-4. 10.5152\/eurasianjmed.2025.25828","journal-title":"Eurasian J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/currents.eogt.761b81608129ed61b0b48d42c04f92a4","article-title":"A 22 gene-expression assay, Decipher\u00ae (Genomedx Biosciences) to predict five-year risk of metastatic prostate cancer in men treated with radical prostatectomy","volume":"7","author":"Marrone M","year":"2015","unstructured":"Marrone M, Potosky AL, Penson D, Freedman AN. A 22 gene-expression assay, Decipher\u00ae (Genomedx Biosciences) to predict five-year risk of metastatic prostate cancer in men treated with radical prostatectomy. PLoS Curr. 2015, 7:10.1371\/currents.eogt.761b81608129ed61b0b48d42c04f92a4","journal-title":"PLoS Curr"},{"key":"ref11","article-title":"Prostate Cancer","year":"2026","unstructured":"Prostate Cancer. National Comprehensive Cancer Network, 2026."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.6086","article-title":"Regional adoption of commercial gene expression testing for prostate cancer","volume":"7","author":"Leapman MS","year":"2021","unstructured":"Leapman MS, Wang R, Ma S, Gross CP, Ma X. Regional adoption of commercial gene expression testing for prostate cancer. JAMA Oncol. 2021, 7:52-8. 10.1001\/jamaoncol.2020.6086","journal-title":"JAMA Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath NK","year":"2021","unstructured":"Jairath NK, Dal Pra A, Vince R Jr, et al.. A systematic review of the evidence for the decipher genomic classifier in prostate cancer. Eur Urol. 2021, 79:374-83. 10.1016\/j.eururo.2020.11.021","journal-title":"Eur Urol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-019-0167-9","article-title":"Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance","volume":"23","author":"Herlemann A","year":"2020","unstructured":"Herlemann A, Huang HC, Alam R, et al.. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis. 2020, 23:136-43. 10.1038\/s41391-019-0167-9","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-019-0185-7","article-title":"Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy","volume":"23","author":"Marascio J","year":"2020","unstructured":"Marascio J, Spratt DE, Zhang J, et al.. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer Prostatic Dis. 2020, 23:295-302. 10.1038\/s41391-019-0185-7","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00428-y","article-title":"Impact of Decipher biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative","volume":"25","author":"Vince RA Jr","year":"2022","unstructured":"Vince RA Jr, Jiang R, Qi J, et al.. Impact of Decipher biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. Prostate Cancer Prostatic Dis. 2022, 25:677-83. 10.1038\/s41391-021-00428-y","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.007","article-title":"Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09\/10 randomized clinical trial","volume":"33","author":"Dal Pra A","year":"2022","unstructured":"Dal Pra A, Ghadjar P, Hayoz S, et al.. Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09\/10 randomized clinical trial. Ann Oncol. 2022, 33:950-8. 10.1016\/j.annonc.2022.05.007","journal-title":"Ann Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71690","article-title":"Systematic review of genomic-based risk stratification in localised prostate cancer treatment optimisation: clinical impact and health economic evidence","volume":"15","author":"Lyu J","year":"2026","unstructured":"Lyu J, He F, Corcoran NM, Chen G, Akbarzadeh Khorshidi H. Systematic review of genomic-based risk stratification in localised prostate cancer treatment optimisation: clinical impact and health economic evidence. Cancer Med. 2026, 15:e71690. 10.1002\/cam4.71690","journal-title":"Cancer Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-018-0101-6","article-title":"Validation of the Decipher test for predicting adverse pathology in candidates for prostate cancer active surveillance","volume":"22","author":"Kim HL","year":"2019","unstructured":"Kim HL, Li P, Huang HC, et al.. Validation of the Decipher test for predicting adverse pathology in candidates for prostate cancer active surveillance. Prostate Cancer Prostatic Dis. 2019, 22:399-405. 10.1038\/s41391-018-0101-6","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2026.01.006","article-title":"A high Decipher genomic risk score is associated with major pathological progression in patients undergoing active surveillance for prostate cancer","author":"Shee K","year":"2026","unstructured":"Shee K, Pace WA, Song JJ, et al.. A high Decipher genomic risk score is associated with major pathological progression in patients undergoing active surveillance for prostate cancer. Eur Urol Oncol. 2026, 10.1016\/j.euo.2026.01.006","journal-title":"Eur Urol Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPZ7WBU9YXSJPE","article-title":"Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome","volume":"136","author":"Iczkowski KA","year":"2011","unstructured":"Iczkowski KA, Torkko KC, Kotnis GR, et al.. Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol. 2011, 136:98-107. 10.1309\/AJCPZ7WBU9YXSJPE","journal-title":"Am J Clin Pathol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3976-z","article-title":"Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations","volume":"18","author":"B\u00f6ttcher R","year":"2018","unstructured":"B\u00f6ttcher R, Kweldam CF, Livingstone J, et al.. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer. 2018, 18:8. 10.1186\/s12885-017-3976-z","journal-title":"BMC Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23005","article-title":"The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer","volume":"75","author":"Chen Z","year":"2015","unstructured":"Chen Z, Chen N, Shen P, et al.. The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer. Prostate. 2015, 75:1247-54. 10.1002\/pros.23005","journal-title":"Prostate"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001290","article-title":"The prognostic impact of intraductal carcinoma of the prostate: a systematic review and meta-analysis","volume":"204","author":"Miura N","year":"2020","unstructured":"Miura N, Mori K, Mostafaei H, et al.. The prognostic impact of intraductal carcinoma of the prostate: a systematic review and meta-analysis. J Urol. 2020, 204:909-17. 10.1097\/JU.0000000000001290","journal-title":"J Urol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/503258-association-of-histopathologic-characteristics-in-diagnostic-prostate-biopsies-with-decipher-genomic-classifier-risk-groups","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:08:32Z","timestamp":1784830112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/503258-association-of-histopathologic-characteristics-in-diagnostic-prostate-biopsies-with-decipher-genomic-classifier-risk-groups"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.113243","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}